Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

1. How effective are bisphosphonates and denosumab in preventing fractures in post-menopausal women?

How effective are bisphosphonates and denosumab in preventing fractures in post-menopausal women? January 25, 2021 Osteoporosis treatment for post-menopausal women Clinical Question: How effective are bisphosphonates and denosumab in preventing fractures in post-menopausal women? Bottom Line: Bisphosphonates and denosumab are similarly effective at reducing risk of fracture in post-menopausal women. Over 1-4 years, bisphosphonates or denosumab provide an absolute reduction of ~0.5-1.0% for hip (...) : Relative risk 0.74 versus 0.81. • Vertebral fracture: Relative risk 0.60 versus 0.53. o Denosumab: ? Five systematic reviews 5,6,10,13,14 compared denosumab versus placebo: Absolute event rates by fracture type not reported. ? Largest RCT 15 (7868 post-menopausal women, T-score =-2.5) compared denosumab and placebo over 3 years: • Hip fracture: 0.7% versus 1.1% placebo, NNT=230. • Non-vertebral fracture: 6.1% versus 7.5% placebo, NNT=72. • Vertebral fracture: 2.3% versus 7.1% placebo, NNT=21. o

2021 Tools for Practice

2. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association | Circulation Search Search Hello Guest! Login to your account Email Password Keep me logged in Search Search December 2020 November 2020 October 2020 September 2020 August 2020 July (...) 2020 June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access Review Article Share on Jump to Free Access Review Article Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association , PhD, MPH, FAHA, Chair , EdD, MS, FAHA , PhD, FAHA , MD, FAHA , MD, MS, MBA , MD, MPH, FAHA , MD, FAHA

2020 American Heart Association

3. Genitourinary syndrome of menopause

Genitourinary syndrome of menopause Downloaded from https://journals.lww.com/menopausejournal by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3POoLCqWplEd8Bo1CEdC/oIL2wQGXkCkcc+vvIcnqPqs= on 08/27/2020 Downloaded from https://journals.lww.com/menopausejournal by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3POoLCqWplEd8Bo1CEdC/oIL2wQGXkCkcc+vvIcnqPqs= on 08/27/2020 NAMS POSITION STATEMENT The 2020 genitourinary syndrome of menopause position statement (...) of The North American Menopause Society Abstract Objective: To update and expand the 2013 position statement of The North American Menopause Society (NAMS) on the management of the genitourinary syndrome of menopause (GSM), of which symptomatic vulvovaginal atrophy (VVA) is a component. Methods: A Panel of acknowledged experts in the field of genitourinary health reviewed the literature to evaluate new evidence on vaginal hormone therapies as well as on other management options available or in development

2020 The North American Menopause Society

4. The Effectiveness of Prasterone vs Placebo Therapy as the Vulvovaginal Atrophy Treatment in Menopausal Women: Meta-Analysis Full Text available with Trip Pro

The Effectiveness of Prasterone vs Placebo Therapy as the Vulvovaginal Atrophy Treatment in Menopausal Women: Meta-Analysis THE EFFECTIVENESS OF PRASTERONE VS PLACEBO THERAPY AS THE VULVOVAGINAL ATROPHY TREATMENT IN MENOPAUSAL WOMEN: META-ANALYSIS STUDY | Medical and Health Science Journal Open Menu Search Search / / / Articles Keywords: VULVOVAGINAL ATROPHY, MENOPAUSE, PRASTERONE, PLACEBO, SUPERFICIAL CELL, PARABASAL CELL, VAGINAL PH, DISPAREUNIA Abstract Background : Vulvovaginal atrophy (...) is a condition that often occurs in menopausal women due to Estrogen decreased. Prasterone (DHEA) is a steroid hormone that can be converted into Estrogen in the target tissue . Objective : This paper aims to evaluate the effectiveness of administering Prasterone as Vulvovaginal Atrophy therapy in menopausal women . Methods : A systematic data search was performed on a medical database (PUBMED, Google scholar, Cochrane). Inclusion criteria: (1) randomized study of Prasterone as Vulvovaginal Atrophy therapy

2020 Medical and Health Science Journal

5. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. Full Text available with Trip Pro

Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. The influence of menopausal hormone therapy on breast cancer remains unsettled with discordant findings from observational studies and randomized clinical trials.To assess the association of prior randomized use of estrogen plus progestin or prior randomized use of estrogen alone with breast cancer incidence and mortality

2020 JAMA

6. Association between HDL-C levels and menopause: a meta-analysis Full Text available with Trip Pro

Association between HDL-C levels and menopause: a meta-analysis Association between HDL-C levels and menopause: a meta-analysis | SpringerLink Search Search SpringerLink Search Association between HDL-C levels and menopause: a meta-analysis Association between HDL-C levels and menopause: a meta-analysis , , , , , , , , , , & , ( 2020 ) 519 Accesses 1 Altmetric Abstract Purpose Menopause modifies women’s lipid profiles. However, the fact that it is still unclear whether high-density lipoprotein (...) not different in this first meta-analysis of lipid profiles in premenopausal and postmenopausal women. Prospective studies with large populations examining HDL-C levels and functions in women with different menopausal statuses are essential in the future. Trial registration number None. Introduction The menopause transition is an inevitable physiological process that occurs in women and is characterized by biological changes such as reductions in estradiol levels and proatherogenic lipid profiles

2020 Hormones

7. Non-hormonal-based treatments for menopausal symptoms

Non-hormonal-based treatments for menopausal symptoms Non-hormonal-based treatments for menopausal symptoms | British Menopause Society Search for: Summary consensus statement Non-hormonal-based treatments for menopausal symptoms Non-hormonal-based treatments for menopausal symptoms 2018-04-13T10:06:04+01:00 Summary practice points As clinicians we must be familiar with alternative therapies, to help inform and guide women as to which options are most likely to be beneficial to them. Few (...) complementary and alternative treatment options have proven evidence of effectiveness, but although many options do not stand up to scrutiny from a robust and evidence based perspective there will be individual women who will benefit from some of these treatments. Placebo effect is not inconsiderable and in menopausal studies will play a part in individual experience and reported benefits The full statement, scientific papers, charts, presentations etc are available in the . If you are not a member you can

2020 British Menopause Society

8. Tibolone (Tibella) - for short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause

Tibolone (Tibella) - for short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization

2020 Health Canada - Drug and Health Product Register

9. Contraception - assessment: Scenario: Approaching the menopause

Contraception - assessment: Scenario: Approaching the menopause Scenario: Approaching the menopause | Management | Contraception - assessment | CKS | NICE Search CKS… Menu Scenario: Approaching the menopause Contraception - assessment: Scenario: Approaching the menopause Last revised in September 2019 Scenario: Approaching the menopause How does the approach of menopause influence choice? The UK Medical Eligibility Criteria (UKMEC) also apply to perimenopausal women. For more information, see (...) in women approaching the menopause make this method difficult to use. Combined hormonal contraception (pill, transdermal patch, or vaginal ring) is not contraindicated by age alone in perimenopausal women, however consider the UKMEC for women who are: 35 years of age or older and smoke 15 or more cigarettes a day, who have a history of migraine with aura, or who develop migraine with aura while using combined hormonal contraception. 35 years of age or older and smoke fewer than 15 cigarettes a day

2020 NICE Clinical Knowledge Summaries

10. Menopause

Menopause CLINICAL PROFESSIONAL RESOURCE Menopause RCN guidance for nurses, midwives and health visitors Endorsed by This publication is supported by industryMENOPAUSE 2 This publication is due for review in November 2020. To provide feedback on its contents or on your experience of using the publication, please email publications.feedback@rcn.org.uk Acknowledgements This new publication is based on, and replaces, previous RCN publications – Women’s Health and the Menopause: RCN Guidance (...) for Nurses, Midwives and Health Visitors (RCN, 2005 and 2014) and Complementary Approaches to Menopausal Symptoms: RCN Guidance for Nurses, Midwives and Health Visitors (RCN, 2006). The RCN Women’s Health Forum would like to thank the menopause project team for the development of this publication: Debra Holloway (project chair), Nurse Consultant Gynaecology, Guy’s and St Thomas’ NHS Foundation Trust and Chair of the RCN Women’s Health Forum Carmel Bagness, RCN Professional Lead Midwifery and Women’s

2020 Royal College of Nursing

11. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. Full Text available with Trip Pro

Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. Recent guidelines endorse using history of menopause before age 40 years to refine atherosclerotic cardiovascular disease risk assessments among middle-aged women. Robust data on cardiovascular disease risk in this population are lacking.To examine the development of cardiovascular diseases and cardiovascular risk factors in women with natural and surgical menopause before age 40 years.Cohort study (UK (...) Biobank), with adult residents of the United Kingdom recruited between 2006 and 2010. Of women who were 40 to 69 years old and postmenopausal at study enrollment, 144 260 were eligible for inclusion. Follow-up occurred through August 2016.Natural premature menopause (menopause before age 40 without oophorectomy) and surgical premature menopause (bilateral oophorectomy before age 40). Postmenopausal women without premature menopause served as the reference group.The primary outcome was a composite

2019 JAMA

12. Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial. (Abstract)

Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial. Whether health outcomes of menopausal estrogen therapy differ between women with and without bilateral salpingo-oophorectomy (BSO) is unknown.To examine estrogen therapy outcomes by BSO status, with additional stratification by 10-year age groups.Subgroup analyses of the randomized Women's Health Initiative Estrogen-Alone Trial. (ClinicalTrials.gov: NCT00000611).40 U.S

2019 Annals of Internal Medicine

13. Tribulus terrestris Linn as treatment of menopause symptoms: a systematic review Full Text available with Trip Pro

Tribulus terrestris Linn as treatment of menopause symptoms: a systematic review Tribulus terrestris Linn as treatment of menopause symptoms: a systematic review | Revista Fitos Português (Brasil) Português (Brasil) e-ISSN: 2446-4775 | ISSN: 1808-9569 e-ISSN: 2446-4775 | ISSN: 1808-9569 Contato CTM Farmanguinhos/Fiocruz Av.Comandante Guaranys, 447 Jacarepaguá, Rio de Janeiro CEP 20.775-610 Contato Principal Equipe Editorial +55 (21) 3348-5598 revistafitos@far.fiocruz.br Contato para Suporte (...) Técnico +55 (21) 3348-5369 eugenio.telles@far.fiocruz.br Revisão Tribulus terrestris Linn as treatment of menopause symptoms: a systematic review v. 13 n. 2 (2019) 195-203 19/10/2018 10/09/2019 Amanda Carvalho de Sousa Faculdade Uninassau - Campus Redenção Endereço: R. Dr. Otto Tito, 278-306 - Redenção, Teresina - PI, 64017-772 Graduating in baccalaureate in pharmacy in Faculdade Uninassau - Campus redenção, Teresina-PI. Mizael Araujo Lima Faculdade Uninassau - Campus Redenção Endereço: R. Dr. Otto

2019 Revista Fitos

14. Menopause and the Workplace Guidance: what to consider

Menopause and the Workplace Guidance: what to consider BRITISH MENOPAUSE SOCIETY T ool for clinicians Information for GPs and other health professionals 1 of 3 Menopause and the workplace guidance: what to consider This factsheet provides a ‘how-to’ guide for employers and relevant staff within organisations that are considering writing their own guidance on the menopause. Introduction • In 2019, there are over 4.3million employed women in the UK aged 45-60. 1 • Given the average age (...) of a women’s menopause is 51 years 2 , a significant number of employed women will be working through their menopausal transition. • The experiences of the menopausal transition varies enormously between women. Some women will have no symptoms but most women will experience at least one symptom. 2 Up to a third of women will experience severe menopausal symptoms that can impact on their quality of life. 3,4 • It is the work context that women report greater difficulty in managing symptoms 5,6 and can feel

2019 British Menopause Society

15. British Menopause Society update on HRT supply shortages

British Menopause Society update on HRT supply shortages British Menopause Society further update on HRT supply shortages | British Menopause Society Search for: News 2019-08-23T12:14:14+01:00 23 August 2019 | In response to the ongoing HRT shortages, the British Menopause Society has produced this further update on the current availability of HRT products. This provides guidance to BMS members and clinical practitioners who may be experiencing difficulties with HRT supplies. There continues (...) . Available. Zumenon® 1mg oestradiol and 2mg oestradiol. Shortage of supplies. Elleste Solo™ MX patches 40mcg transdermal oestradiol. Available. Elleste Solo™ MX patches 80mcg transdermal oestradiol. Available. Mylan’s manufacturing partner continues to experience interruptions in the production of certain strengths of Elleste™, their Hormone Replacement Therapy (HRT). They have informed us that they will continue to provide updates on timing for resolution, as they receive them; to the British Menopause

2019 Royal College of Obstetricians and Gynaecologists

16. Testosterone replacement in menopause

Testosterone replacement in menopause BRITISH MENOPAUSE SOCIETY T ool for clinicians Information for GPs and other health professionals 1 of 4 1 How much and where does it come from? Testosterone is an important female hormone. Healthy young women produce approximately 100 – 400 mcg per day. This represents three to four times the amount of estrogen produced by the ovaries. Approximately half of endogenous testosterone and precursors are derived from the ovaries e.g. androstenedione and half (...) from the adrenal glands e.g. dehydroepiandrosterone. Some of the effects are direct and some due to peripheral conversion to estrogen by aromatase. Testosterone levels naturally decline throughout a woman’s lifespan. Loss of testosterone is particularly profound after iatrogenic i.e. surgical and medical menopause and premature ovarian insufficiency when testosterone production decreases by more than 50%. 2 What is its role in women? Testosterone contributes to libido, sexual arousal and orgasm

2019 British Menopause Society

17. The Systematic Review on Clinical Studies of Traditional Korean Medicine Treatment for Obesity in Menopausal Women Full Text available with Trip Pro

The Systematic Review on Clinical Studies of Traditional Korean Medicine Treatment for Obesity in Menopausal Women The Systematic Review on Clinical Studies of Traditional Korean Medicine Treatment for Obesity in Menopausal Women Search for Search All Journals TEXT SIZE | | | | Title Author Keyword | | 폐경 여성의 비만에 응용되는 한방치료에 대한 문헌 고찰 The Systematic Review on Clinical Studies of Traditional Korean Medicine Treatment for Obesity in Menopausal Women J Korean Med Obes Res 2019;19:56-67 Published (...) . This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Objectives: The purpose of this study is to review clinical studies of herb medicine and acupuncture treatment on obesity in menopausal women. Methods: Key words “Obesity”, “Menopause”, “Herb medicine”, “Acupuncture”, “Moxibustion”, “Catgut

2019 Journal of Korean Medicine for Obesity Research

18. Are vaginal estradiol tablets (Vagifem) effective for genitourinary syndrome of menopause?

Are vaginal estradiol tablets (Vagifem) effective for genitourinary syndrome of menopause? Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care (...) research. www.acfp.ca June 10, 2019 Verifying the value of vaginal estradiol tablets Clinical Question: Are vaginal estradiol tablets (Vagifem®) effective for genitourinary syndrome of menopause? Bottom Line: Vaginal estradiol tablets are likely no better than placebo vaginal gel for reducing “most bothersome symptom scores” (mainly dyspareunia). However, compared to placebo vaginal tablets, they reduce symptoms (example: treatment “success” at 12 months in 86% versus 41% placebo). A non-medicated

2019 Tools for Practice

19. Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial (Abstract)

Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial We evaluated the effect of Internet-based cognitive behavioral therapy (iCBT), with or without therapist support, on the perceived impact of hot flushes and night sweats (HF/NS) and overall levels of menopausal symptoms (primary outcomes), sleep quality, HF/NS frequency, sexual functioning, psychological distress, and health (...) -related quality of life in breast cancer survivors with treatment-induced menopausal symptoms.We randomly assigned 254 breast cancer survivors to a therapist-guided or a self-managed iCBT group or to a waiting list control group. The 6-week iCBT program included psycho-education, behavior monitoring, and cognitive restructuring. Questionnaires were administered at baseline and at 10 weeks and 24 weeks postrandomization. We used mixed-effects models to compare the intervention groups with the control

2019 EvidenceUpdates

20. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health

Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health CONSENSUS RECOMMENDATIONS Managementofgenitourinarysyndromeofmenopauseinwomenwith orathighriskforbreastcancer:consensusrecommendationsfromThe North American Menopause Society and The International Society for the Study of Women’s Sexual Health Stephanie S (...) , CCD, NCMP, IF, FACOG, 14 Shari B. Goldfarb, MD, 15 and Sheryl A. Kingsberg, PhD 16 Abstract TheobjectiveofTheNorthAmericanMenopauseSociety(NAMS)andTheInternationalSocietyfortheStudyof Women’s Sexual Health (ISSWSH) Expert Consensus Panel was to create a point of care algorithm for treating genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. The consensus recommendationswillassisthealthcareprovidersinmanagingGSMwithagoalofimprovingthecareandqualityof life

2019 The North American Menopause Society